Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate.

Autor: Zamotaeva MN; N. P. Ogarev Mordovian National Research State University, Saransk, Republic of Mordovia, Russia., Inchina VI; N. P. Ogarev Mordovian National Research State University, Saransk, Republic of Mordovia, Russia., Konorev VV; N. P. Ogarev Mordovian National Research State University, Saransk, Republic of Mordovia, Russia. konarewv@rambler.ru., Kuznetsov YV; N. M. Emanuel Institute of Biochemical Physics, Moscow, Russia., Kuz'michev ND; N. P. Ogarev Mordovian National Research State University, Saransk, Republic of Mordovia, Russia.
Jazyk: angličtina
Zdroj: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2018 Jul; Vol. 165 (3), pp. 344-346. Date of Electronic Publication: 2018 Jul 13.
DOI: 10.1007/s10517-018-4166-y
Abstrakt: The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.
Databáze: MEDLINE
Externí odkaz: